Intellia Therapeutics, Inc.

intelliatx.com

What Do They Do?

Develops CRISPR gene-editing treatments for people with severe diseases, including hereditary angioedema and transthyretin amyloidosis.

How Do They Make Money?

Intellia earns collaboration payments from partners for licensed product rights, research funding and shared development costs. It can also receive upfront fees, milestone payments when goals are met and royalties when licensed products are sold.

FY2025 revenue

Who Are Their Customers?

Intellia works with Regeneron and other research collaborators to develop product candidates; some collaboration agreements license product-candidate rights to third parties.

Do Revenues Turn Into Profits?

No. It lost $412.7M in FY2025.

Operating income, FY2025

−652% of revenue

▼ −17% (Loss) vs FY2024 (−$534.3M, −923%)

Net income, FY2025

−610% of revenue

▼ −20% (Loss) vs FY2024 (−$519M, −897%)

Free cash flow, FY2025

−585% of revenue

▲ +12% (Loss) vs FY2024 (−$354.7M, −613%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue: ▼ −46%; vs $14.2M in Q2 FY2025
Net income: ▲ +5% (Loss); vs −$101.3M in Q2 FY2025

Sep 8, 2026 FDA accepts lonvo-z application and grants priority review The target action date is March 10, 2027; FDA said it is not currently planning an advisory committee.
Aug 6, 2026 Enrollment restarts in nex-z Phase 3 trials Intellia expected MAGNITUDE-2 enrollment in ATTRv-PN to finish in the second half of 2026.
Apr 27, 2026 Phase 3 HAELO trial meets primary and key secondary endpoints Intellia reported positive topline results and began a rolling application submission for U.S. approval.

Growing. Revenue grew 2.0x in 4 years, from $33.1M in FY2021 to $67.7M in FY2025, about 20% a year.

Focus on later-stage medicines The older report described gene-editing treatments for liver diseases and engineered-cell treatments for cancer and autoimmune diseases. The latest centers on late-stage candidates for hereditary angioedema and transthyretin amyloidosis, alongside earlier-stage programs with partners.

Preparing for commercialization The older report described developing potential therapies, while the latest also describes building U.S. sales and medical teams and preparing payer, distribution and pricing plans for a potential launch.

Who Do They Compete With?

Competes with ADARx Therapeutics, Argo Biopharmaceutical, BioCryst Pharmaceuticals, CSL, Gritgen Therapeutics, Ionis Pharmaceuticals, KalVista Pharmaceuticals, Pharming Group, Pharvaris, Takeda Pharmaceutical, Alnylam Pharmaceuticals, AstraZeneca Pharmaceuticals, BridgeBio Pharma, Bayer, Metagenomi Therapeutics, Novo Nordisk, Pfizer, and YolTech Therapeutics

Comments